The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)

January 2008
BMC Psychiatry;2008, Vol. 8, p95
Academic Journal
No abstract available.


Related Articles

  • Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management. Haddad, Peter M.; Wieck, Angelika // Drugs;2004, Vol. 64 Issue 20, p2291 

    Hyperprolactinaemia is an important but neglected adverse effect of antipsychotic medication. It occurs frequently with conventional antipsychotics and some atypical antipsychotics (risperidone and amisulpride) but is rare with other atypical antipsychotics (aripiprazole, clozapine, olanzapine,...

  • Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. Ranjbar, Fatemeh; Sadeghi-Bazargani, Homayoun; Khams, Parisa Niari; Arfaie, Asghar; Salari, Azim; Farahbakhsh, Mostafa // Neuropsychiatric Disease & Treatment;2015, Vol. 11, p549 

    Background: Antipsychotics have been used for more than 50 years in the treatment of schizophrenia and many other psychiatric disorders. Prolactin levels usually increase in patients treated with risperidone. Aripiprazole, which has a unique effect as an antipsychotic, is a D2 receptor partial...

  • Aripiprazole beats haloperidol-induced hyperprolactinaemia.  // Reactions Weekly;10/27/2007, Issue 1175, p1 

    The article describes the results of a study on the effectiveness of aripiprazole for the treatment of haloperidol-induced hyperprolactinaemia among schizophrenics. Recipients of aripiprazole had significantly lower prolactin levels and seven patients with menstrual disturbances regained...

  • Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. Jenn-Huei Renn; Nan-Ping Yang; Pesus Chou // BMC Musculoskeletal Disorders;2010, Vol. 11, p35 

    Background: Osteoporosis is a bone disease that can reduce both bone mass and bone strength. It can cause serious fractures of bones, along with causing significant and even devastating physical, psychological and financial consequences for patients and their family members. Many reports have...

  • Antipsikotiklere BaÄŸlı Hiperprolaktinemi ve Osteoporoz. Temiz, Semiha Tufan; Erol, Atila // Klinik Psikofarmakoloji Bulteni;Dec2008 Supplement, Vol. 18, pS62 

    Antipsychotic drugs block dopamine D2 receptors and thus remove the inhibitory influence on prolactin secretion. Hyperprolactinemia is a common side effect of treatment with antipsychotics. Altough It has been recognized that traditional antipsychotic drugs cause symptomatic hyperprolactinemia,...

  • Aripiprazole for schizophrenia: Systematic review. El-Sayeh, H. G.; Morganti, C.; Adams, C. E. // British Journal of Psychiatry;Aug2006, Vol. 189, p102 

    Background Aripiprazole is an atypical antipsychotic that is reported to be effective in the treatment of schizophrenia. Aims To investigate the effects of aripiprazole on patients with schizophrenia and schizophrenia-like psychoses by conducting a systematic review of randomised controlled...

  • Aripiprazole-induced oculogyric crisis (acute dystonia). Bhachech, Jyotik T. // Journal of Pharmacology & Pharmacotherapeutics;Jul-Sep2012, Vol. 3 Issue 3, p279 

    Aripiprazole is the third generation atypical antipsychotic and a dopamine serotonin system stabilizer (DSS) effective against positive and negative symptoms of schizophrenia. It has a low propensity for extrapyramidal side effects, causes minimal weight gain or sedation, produces no elevation...

  • Aripiprazole is the STAR for cost effectiveness in schizophrenia.  // PharmacoEconomics & Outcomes News;2/5/2011, Issue 621, p5 

    The article discusses research on the cost effectiveness of aripiprazole in patients with schizophrenia, which references the study "Cost-Effectiveness Analysis of Aripiprazole vs. Standard-of-Care in the Management of Community-Treated Patients With Schizophrenia: STAR Study," by D. King et al,...

  • Antipsikotik Tedavi Uygulanan Åžizofreni Hastalarında Prolaktin Düzeyleri ve Cinsel Ä°ÅŸlevlerin Cinsiyetlere Göre KarşılaÅŸtırılması. DOĞU, Basri; KOCABIYIK, Ahmet; KARSON, Fahri; ÇITAK, Serhat; İNCESU, Cem // Archives of Neuropsychiatry / Noropsikiatri Arsivi;Mar2011 Supplement, Vol. 48, p35 

    This study was set out to research the inter-sexual differences in the relation between prolactin levels and sexual dysfunction, independently from the type and dosage of anti-psychotic medicine used in schizophrenia patients treated at the outpatient treatment unit of Bakırköy State...

  • WpÅ‚yw poneuroleptycznej hiperprolaktynemii na wystÄ™powanie zaburzeÅ„ seksualnych u mężczyzn chorych na schizofreniÄ™. Konarzewska, Beata; Szulc, Agata; Popławska, Regina; Galińska, Beata; Juchnowicz, Dariusz // Psychiatria Polska;2008, Vol. 42 Issue 1, p87 

    Human sexual function is complex and effected in many different ways by schizophrenia and the antipsychotic drugs used in its treatment. Although not extensively researched, sexual dysfunction seems to be frequent in patients with schizophrenia, especially in men. They appear, in significant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics